Severe vascular-degenerative diseases afflict millions of patients worldwide. Treatment options are limited. There are no cures.


Critical limb ischemia (CLI) is an unmet medical need.

Peripheral artery disease (PAD), a circulatory condition in which narrowed arteries reduce blood flow to limbs, affects over 200 million people worldwide. PAD is increasing in prevalence as as populations age, and in association with growing incidence of diabetes.

Critical limb ischemia (CLI), the severe form of PAD, is diagnosed in 500,000 patients each year. Many of these patients require amputation, and half die within 5 years. Medical claims for CLI patients in the US are on the order of ~$3.6 billion per year.


New therapeutic modalities are needed to help these patients. We are developing regenerative medicines designed to repair the vasculature. 


Stem cell derived vascular progenitors can form new vessels.

Regenerative medicine offers a new opportunity to develop treatments for intractable degenerative conditions. Vascugen is advancing a pipeline of cell therapeutics designed to restore function to tissues where blood flow has been restricted due to disease.

Our Founder, Mervin C. Yoder, MD, is a leading expert and pioneer in the biology of endothelial progenitor cells. He has shown that certain populations of these cells have the potential to form healthy blood vessels, and thereby rescue function in animal models of CLI.


The focus of my research over the past decade has been on the discovery and characterization of unique endothelial cell populations that have demonstrated capacity to form new blood vessels in vivo. At Vascugen we are translating these discoveries into therapeutic candidates targeting a range of vascular degenerative conditions, starting with critical limb ischemia (CLI).
— Mervin C. Yoder, MD, Chief Scientific Officer
Treatment options for patients with critical limb ischemia (CLI) are limited and major amputation surgery is often required, which significantly reduces quality of life and increases mortality from cardiovascular complications. New interventions are needed for these patients, and stem cell based regenerative medicines designed to restore vascular function is a promising approach.
— Michael P. Murphy, MD, Clinical Advisor